Phase 3 N=141 Treating Violence-Prone Substance Use Disorder Patients
Substance-related Disorders · Violence
Primary: Addiction Severity Index Legal Composite — .038; .012 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=2,057 The Tobacco, Alcohol, Prescription Medication and Other Substances Tool
Substance Use Disorder
Primary: Diagnostic and Statistical Manual-5 (DSM-5) Alcohol Use Disorder Diagnosis Measured by the Modified World Mental Health Composite International Diagnostic Interview…
N/A N=86 Feasibility of SBIRT-PN
Substance Use · HIV/AIDS · Older Adults
Primary: Number of Participants Ranking Intervention as Acceptable — 9; 5 Participants
N/A N=200 Women's Treatment and Early Recovery
Substance-related Disorders
Primary: Treatment Completion — 43; 31 Number of women — p=<0.05
N/A N=152 A Therapeutic Workplace to Address Poverty and Substance Use
Substance Use Disorders
Primary: Alcohol Abstinence — 82.8; 60.2 percentage of participants — p=<0.001
N/A N=153 Treatment for Adolescent Marijuana Abuse
Marijuana Abuse
Primary: Marijuana Abstinence (2 Weeks or Greater) — 72.5; 68.6; 45.1 percentage of participants
Phase 2 N=48 Cognitive Remediation and Work Therapy in the Initial Phase of Substance Abuse Treatment
Substance Abuse · Substance Dependence · Cognitive Impairment
Primary: Days of Sobriety in First 90 Days — 87.3; 84.64 Days of Sobriety — p=.55
Phase 2 N=183 Therapeutic Substance Abuse Treatment in Pregnancy - 1
Alcohol Abuse · Cocaine Abuse · Marijuana Abuse
Primary: Percentage of Days Used Drugs or Alcohol — 18; 21; 6; 7 percentage of days — p=0.88
N/A N=2,695 Screening and Brief Advice to Reduce Teen Substance Use
Substance Related Disorders
Primary: Past-90-day Substance Use at 3 Months Among Baseline Substance Users - New England, USA — 162; 121 Participants — p=< 0.05
N/A N=250 Survey to Identify Substance Use in Teenagers and Adolescents
Anesthesia
Primary: Number of Participants With Adolescent and Parent Reported Alcohol, Drug, Vaping and Tobacco Usage — 1; 1; 0; 425 Participants
Phase 4 N=105 Bupropion for ADHD in Adolescents With Substance Use Disorder
Attention Deficit Hyperactivity Disorder · Nicotine Dependence · Cannabis Use Disorder
Primary: Change in ADHD Rating Scale (ADHD-RS) Total Score — -14.2; -13.8 units on a scale
N/A N=122 Adolescents With Substance Use Disorders Transitioníng From Residential Treatment to the Community
Substance Use · Adolescent Behavior
Primary: Change in Proportion of Days Used Outside of Controlled Environment — .27; .35; .35; .32 proportion of days used — p=.12
N/A N=667 LINK: Aftercare Monitoring Project
Alcohol Dependence · Drug Dependence
Primary: Rates of Substance Use — 91.1; 88.0 percentage of days
N/A N=59 Behavioral Treatment of Adolescent Substance Use
Substance Use Disorders
Primary: Any Cannabis Abstinence — 13; 18 participants
N/A N=129 Enhancing Adolescent Substance Abuse Treatment
Substance Use Disorders
Primary: Changes From Baseline Scores Compared to Post-Treatment Scores, Any Positive Youth Urine Drug/Alcohol Screens (Measured at 0, 2, 4, 6, 9, & 12 Months). — 0.68; 0.73…
N/A N=29 Initiating Substance Use Disorder Treatment for Hospitalized Opioid Use Disorder Patients.
Opioid-use Disorder
Primary: Treatment Retention — 5; 5 Participants — p==0.87
N/A N=5,706 Computerized Substance Use and Depression Screening and Behavioral Treatment in HIV Primary Care
Substance Use Disorders · HIV · Depression
Primary: Change in Mental Health and Substance Use Screening Rates — 2008; 2379 Participants
N/A N=66 Women Veterans' Substance Abuse Treatment
Substance Use Disorders
Primary: Addiction Severity Index Alcohol Composite — .36; .46; .18; .26 units on a scale
N/A N=287 Dual Diagnosis Self-Help Referral
Dual Diagnosis
Primary: Psychiatric Functioning at 6 Months — .333; .387 units on a scale
N/A N=79 Leveraging Technology to Address Unhealthy Drug Use in Primary Care Settings
Addiction
Primary: Receipt of Brief Intervention (BI) for Drug Use at Baseline Visit — 17; 33 Participants
N/A N=257 Mindfulness Mobile App to Reduce Adolescent Substance Use
Adolescent Drinking · Adolescent Problem Behavior
Primary: Number of Participants With Marijuana Use — 47; 40; 41; 41 Participants — p=.962
N/A N=69 Individual and Family Motivational Interviews for Substance Using Truant Teens
Substance Use
Primary: Marijuana Use Days in Past 90 Days — 35; 45; 27; 41 days
N/A N=46 Targeting Self-regulatory Deficits Through Cognitive Remediation Intervention
Drug Use Disorders
Primary: Change in Stop Signal Reaction Time — -8.62 ms — p=.003
Phase 2 N=107 Interactive Motivational Media for Perinatal Drug Abuse - 3
Substance-Related Disorders
Primary: Number of Participants With Drug Use at 3 Months — 49; 48 participants
N/A N=81 Integrated Treatment of OEF/OIF Veterans With PTSD & Substance Use Disorders
Posttraumatic Stress Disorders · Combat Disorders · Alcohol Dependence
Primary: Change in Post-traumatic Stress Disorder Symptomatology — -51.2; -35.9; -22.3; -10.9 score on a scale
N/A N=20 Pilot: Digital Therapeutic vs Education for the Management of Problematic Substance Use
Alcohol Use Disorder (AUD) · Substance Use Disorders
Primary: Change in Number of Substance Use Occasions — -0.6; -7.2; -3.9; -6.7 occasions
Phase 1 N=101 Woebot for Substance Use Disorders
Substance Use Disorders
Primary: Change in Alcohol Use Disorders Identification Test-Consumption (AUDIT-C) From Baseline to Post-treatment at 8 Weeks — -9.3 score on a scale
N/A N=78 Stress, Distress Intolerance, and Drug Dependence
Substance Dependence
Primary: Percentage of Positive Toxicology Swabs for Illicit Substances — 81.3; 79.1; 86.2; 82.3 percentage of positive toxicology screen
N/A N=88 Substance Use Treatment and Recovery Team (START)
Opioid-use Disorder · Opioid-Related Disorders · Alcohol Use Disorder
Primary: Number of Patients With In-hospital Initiation of Medication for OUD or AUD — 22; 9 Participants — p=<.001
Phase 2 N=17 Medication Development for Opioid and Alcohol Abuse
Opioid-use Disorder · Alcohol Use Disorder
Primary: Peak Positive Subjective Responses to Placebo. — 3.3; 2.3 units on a scale